AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - What's Next?

Key Points

• Shares gapped up Tuesday, opening at $5.05 after a $4.59 close and last trading around $4.805 on heavy volume (~5.13M shares), signaling renewed short-term interest.
• The stock carries a consensus rating of "Moderate Buy" with an average analyst target of $8.17, reflecting mixed but generally positive coverage (one Strong Buy, four Buy, one Hold, one Sell) and recent new coverage from JonesTrading and Cantor Fitzgerald.
• Recent results showed an earnings beat (EPS -$0.03 vs. -$0.18 est.) and a large revenue beat ($44.85M vs. $6.31M), but the company remains unprofitable (negative net margin ~198%, negative ROE) with a market cap of about $1.42B and expected FY EPS of -0.89.

AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $4.59, but opened at $5.05. AbCellera Biologics shares last traded at $4.8050, with a volume of 5,130,878 shares.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. JonesTrading assumed coverage on AbCellera Biologics in a report on Friday, April 10th. They set a "buy" rating and a $11.00 target price on the stock. Wall Street Zen raised AbCellera Biologics from a "sell" rating to a "hold" rating in a report on Saturday, February 14th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AbCellera Biologics in a report on Monday, April 20th. Finally, Cantor Fitzgerald assumed coverage on AbCellera Biologics in a report on Tuesday. They set an "overweight" rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, AbCellera Biologics presently has a consensus rating of "Moderate Buy" and an average target price of $8.17.

AbCellera Biologics Stock Performance

The firm has a market cap of $1.42 billion, a P/E ratio of -9.50 and a beta of 1.02. The firm has a fifty day moving average of $3.60 and a 200-day moving average of $3.86.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.15. The business had revenue of $44.85 million for the quarter, compared to the consensus estimate of $6.31 million. AbCellera Biologics had a negative return on equity of 15.05% and a negative net margin of 198.37%. Equities research analysts expect that AbCellera Biologics Inc. will post -0.89 earnings per share for the current year.

Institutional Trading of AbCellera Biologics

Hedge funds have recently made changes to their positions in the stock. State of Michigan Retirement System lifted its holdings in shares of AbCellera Biologics by 712.6% in the 3rd quarter. State of Michigan Retirement System now owns 400,000 shares of the company's stock worth $2,012,000 after purchasing an additional 350,775 shares during the last quarter. Citizens Financial Group Inc. RI bought a new stake in shares of AbCellera Biologics in the 3rd quarter worth approximately $1,317,000. DNB Asset Management AS bought a new stake in shares of AbCellera Biologics in the 3rd quarter worth approximately $3,301,000. Tudor Investment Corp ET AL bought a new stake in shares of AbCellera Biologics in the 3rd quarter worth approximately $3,673,000. Finally, Invesco Ltd. lifted its holdings in shares of AbCellera Biologics by 114.6% in the 1st quarter. Invesco Ltd. now owns 24,146 shares of the company's stock worth $54,000 after purchasing an additional 12,893 shares during the last quarter. Institutional investors own 61.42% of the company's stock.

AbCellera Biologics Company Profile

AbCellera Biologics Inc NASDAQ: ABCL is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company's technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.